Skip to main content

Advertisement

SpringerLink
Log in

PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

Not applicable.

Abbreviations

PSMA:

prostate-specific membrane antigen

PET:

positron emitting tomography

CT:

computed tomography

References

  1. Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K, et al. Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imag. [Internet]. 2023 [cited 2023 Jul 14]; Available from: https://doi.org/10.1007/s00259-023-06332-y

  2. Subramanian K, Martinez J, Castellanos SH, Ivanidze J, Nagar H, Nicholson S, et al. Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men. Sci Rep. 2023;13:8321.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Molecular Imaging and Therapeutics, Department of Radiology, Weill Cornell Medicine, New York, NY, 10065, USA

    Kritika Subramanian & Joseph R. Osborne

Authors
  1. Kritika Subramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph R. Osborne
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KS and JO wrote jointly, reviewed, and approved the submitted letter.

Corresponding author

Correspondence to Kritika Subramanian.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Subramanian, K., Osborne, J.R. PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary. Eur J Nucl Med Mol Imaging 50, 3509–3510 (2023). https://doi.org/10.1007/s00259-023-06378-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-023-06378-y

Search

Navigation